Drug Repurposing Patent Applications October-December 2024.

IF 1.7 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Assay and drug development technologies Pub Date : 2025-08-01 Epub Date: 2025-07-21 DOI:10.1177/1540658X251361263

Hermann A M Mucke

引用次数: 0

Abstract

Here, we briefly discuss 17 PCT patent applications related to drug repurposing that were published during the final quarter of 2024. As always, we have chosen the documents based on significance only, which gave us a wide range of applicants, active agents, and geographic representation. Applicants are not only from the United States and China but also from Japan, Germany, the United Kingdom, Canada, and even remote places such as Algeria and Iceland. Significantly, the contribution from Iceland is how to induce therapeutic hypothermia-but with entacapone, used in Parkinson's disease. The UK company, HealX, presents data showing that Angelman syndrome, an intractable neurodevelopmental disorder, could be treated with the common NSAID sulindac. Gliclazide, an old antidiabetic, could potentially treat schizophrenia, as inventors from Chinese Ping An-Shionogi report. These are only a few highlights from the stream of documents that have been issued towards the end of 2024.

查看原文本刊更多论文

药物再利用专利申请2024年10月至12月。

在这里，我们简要讨论了2024年最后一个季度公布的17项与药物再利用相关的PCT专利申请。一如既往，我们只根据重要性来选择文件，这给了我们广泛的申请人，活跃的代理和地理代表性。申请者不仅来自美国和中国，还有来自日本、德国、英国、加拿大，甚至遥远的地方，如阿尔及利亚和冰岛。值得注意的是，冰岛的贡献在于如何诱导治疗性低温——但使用的是用于帕金森病的恩他卡朋。英国HealX公司提供的数据显示，Angelman综合征，一种难治性神经发育障碍，可以用常见的非甾体抗炎药sulindac治疗。格列齐特，一种古老的抗糖尿病药物，有可能治疗精神分裂症，来自中国的发明者平安-盐野义报道。这些只是2024年底发布的一系列文件中的几个亮点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Assay and drug development technologies 医学-生化研究方法

CiteScore

3.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application. ASSAY and Drug Development Technologies coverage includes: -Assay design, target development, and high-throughput technologies- Hit to Lead optimization and medicinal chemistry through preclinical candidate selection- Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis- Approaches to assays configured for gene families, inherited, and infectious diseases- Assays and strategies for adapting model organisms to drug discovery- The use of stem cells as models of disease- Translation of phenotypic outputs to target identification- Exploration and mechanistic studies of the technical basis for assay and screening artifacts